Figure 6

Breviscapine retarded tumor growth in vivo. (A, B) Tumor weight and volume were assessed in the control with the breviscapine 40 mg/kg and 5-FU 25 mg/kg groups. (C) The Ki-67 protein expression was validated through IHC assay in the control, breviscapine 40 mg/kg, and 5-FU 25 mg/kg groups. ***p < 0.001 versus control.